---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-130383"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:22:10.272012+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences reports 2025 net loss $106.2M; Phase 3 CoMpass enrollment to complete mid-2026

## Summary
- Cash and equivalents $144.2M as of Dec 31, 2025; sufficient to fund operations into Q1 2027.
- Phase 3 CoMpass trial enrollment completion expected by mid-2026; topline data in 2H 2027.
- Phase 1b/2 NMIBC trial initial 3-month clinical data on track for mid-2026.
- New formulation for non-ocular solid tumors achieved 12-month stability; patent filed for coverage into 2046.
- Net loss for 2025 was $106.2M vs $86.9M in 2024; R&D expenses increased to $90.3M.

## SEC filing metadata
- accession: 0001193125-26-130383
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000119312526130383/0001193125-26-130383-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000119312526130383/aura-20260330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-130383
- JSON: https://secwatch.observer/filing/0001193125-26-130383.json
- Plain text: https://secwatch.observer/filing/0001193125-26-130383.txt

## Key facts
- Earnings Releases
  Aura Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2025.
  - Period: the fourth quarter and year ended December 31, 2025
  - Result: reported results
  source text: Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided recent business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501796/000119312526130383/0001193125-26-130383-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.